Synthesis of the Deacetoxytubuvaline Fragment of Pretubulysin and its Lipophilic Analogues for Enhanced Permeability in Cancer Cell Lines

Ramesh B. Reddy; Premansh Dudhe; Venkatesh Chelvam

doi:10.1055/s-0037-1611359

Synlett, Inhaltsverzeichnis

Synlett 2019; 30(01): 77-81
DOI: 10.1055/s-0037-1611359

letter

Synthesis of the Deacetoxytubuvaline Fragment of Pretubulysin and its Lipophilic Analogues for Enhanced Permeability in Cancer Cell Lines

Ramesh B. Reddy

^aDiscipline of Chemistry, Indian Institute of Technology Indore, Khandwa Road, Simrol, Indore-453 552, India

,

Premansh Dudhe

^aDiscipline of Chemistry, Indian Institute of Technology Indore, Khandwa Road, Simrol, Indore-453 552, India

,

Venkatesh Chelvam*

^aDiscipline of Chemistry, Indian Institute of Technology Indore, Khandwa Road, Simrol, Indore-453 552, India

^bDiscipline of Biosciences and Biomedical Engineering, Indian Institute of Technology Indore, Khandwa Road, Simrol, Indore-453 552, India eMail: cvenkat@iiti.ac.in

› Institutsangaben

Abstract

Alle Artikel dieser Rubrik

Abstract

In the last two decades, tubulysins have emerged as alternatives to microtubule depolymerizing agents such as colchicine and vinblastine, which are well-established anticancer agents. However, the complex structure of tubulysins has always posed a challenge for synthetic chemists to scale up the production of these compounds. We report a new strategy for the practical gram-scale synthesis of a (4R)-4-[(tert-butoxycarbonyl)amino]-5-methylhexanoic acid through regioselective cleavage of a chiral aziridine ring with a vinyl Grignard reagent to afford tert-butyl [(1R)-1-isopropylbut-3-en-1-yl]carbamate, which was subjected to regioselective hydroboration–oxidation with 9-BBN. The resulting (4R)-4-[(tert-butoxycarbonyl)amino]-5-methylhexanoic acid was successfully transformed into the deacetoxytubuvaline fragment of pretubulysin or its highly lipophilic methyl-substituted thiazole and oxazole analogues for incorporation into pretubulysins. Increasing the lipophilicity of tubulysin or pretubulysin molecules should enhance their cell permeability and cytotoxicity in cancer cell lines.

Key words

amino acid - deacetoxytubuvaline - tubulysin - pretubulysin - medicinal chemistry

Volltext

Referenzen

References and Notes
1 Mukhtar E, Adhami VM, Mukhtar H. Mol. Cancer Ther. 2014; 13: 275
2 Sasse F, Steinmetz H, Heil J, Höfle G, Reichenbach H. J. Antibiot. 2000; 53: 879
3 Sandmann A, Sasse F, Müller R. Chem. Biol. 2004; 11: 1071
4 Wang Z, McPherson PA, Raccor BS, Balachandran R, Zhu G, Day BW, Vogt A, Wipf P. Chem. Biol. Drug Des. 2007; 70: 75
5 Rath S, Liebl J, Fürst R, Ullrich A, Burkhart JL, Kazmaier U, Herrmann J, Müller R, Günther M, Schreiner L, Wagner E, Vollmar AM, Zahler S. Br. J. Pharmacol. 2012; 167: 1048
6 Staben LR, Yu S.-F, Chen J, Yan G, Xu Z, Del Rosario G, Lau JT, Liu L, Guo J, Zheng B, dela Cruz-Chuh J, Lee BC, Ohri R, Cai W, Zhou H, Kozak KR, Xu K, Phillips GD. L, Lu J, Wai J, Polson AG, Pillow TH. ACS Med. Chem. Lett. 2017; 8: 1037
7 Murray BC, Peterson MT, Fecik RA. Nat. Prod. Rep. 2015; 32: 654
8 Herrmann J, Elnakady YA, Wiedmann RM, Ullrich A, Rohde M, Kazmaier U, Vollmar AM, Müller R. PLoS One 2012; 7: e37416
9 Braig S, Wiedmann RM, Liebl J, Singer M, Kubisch R, Schreiner L, Abhari BA, Wagner E, Kazmaier U, Fulda S, Vollmar AM. Cell Death Dis. 2014; 5: e1001
10 Eirich J, Burkhart JL, Ullrich A, Rudolf GC, Vollmar A, Zahler S, Kazmaier U, Sieber SA. Mol. BioSyst. 2012; 8: 2067
11 Truebenbach I, Gorges J, Kuhn J, Kern S, Baratti E, Kazmaier U, Wagner E, Lächelt U. Macromol. Biosci. 2017; 17: 1600520
12 Ullrich A, Herrmann J, Müller R, Kazmaier U. Eur. J. Org. Chem. 2009; 6367
13 Nicolaou KC, Erande RD, Yin J, Vourloumis D, Aujay M, Sandoval J, Munneke S, Gavrilyuk J. J. Am. Chem. Soc. 2018; 140: 3690
14 Brindisi M, Maramai S, Grillo A, Brogi S, Butini S, Novellino E, Campiani G, Gemma S. Tetrahedron Lett. 2016; 57: 920
15 Colombo R, Wang Z, Han J, Balachandran R, Daghestani HN, Camarco DP, Vogt A, Day BW, Mendel D, Wipf P. J. Org. Chem. 2016; 81: 10302
16 Trabocchi A, Guarna F, Guarna A. Curr. Org. Chem. 2005; 9: 1127
17 Ordóñez M, Cativiela C. Tetrahedron: Asymmetry 2007; 18: 3
18 Menche D, Hassfeld J, Li J, Rudolph S. J. Am. Chem. Soc. 2007; 129: 6100
19 Stark M, Assaraf YG. Oncotarget 2017; 8: 49973; DOI: 10.18632/oncotarget.18385
20 Wipf P, Takada T, Rishel MJ. Org. Lett. 2004; 6: 4057
21 Shankar PS, Sani M, Saunders FR, Wallace HM, Zanda M. Synlett 2011; 1673

22a Kitir B, Baldry M, Ingmer H, Olsen CA. Tetrahedron 2014; 70: 7721
22b Ye W, Leow D, Goh SL. M, Tan C.-T, Chian C.-H, Tan C.-H. Tetrahedron Lett. 2006; 47: 1007

23 Methyl 2-{(3R)-3-[(tert-Butoxycarbonyl)(methyl)amino]-4-methylpentyl}-1,3-thiazole-4-carboxylate (1) Anhyd DMF (2 mL) was added to the thiazole ethyl ester 11 (0.080 g, 0.22 mmol) in a 10 mL round-bottomed flask equipped with a magnetic stirrer bar. MeI (0.05 mL, 0.89 mmol) was then added, and the mixture was cooled to 0 °C. NaH (0.013 g, 0.55 mmol) was added portionwise over 15 min with constant stirring, and the mixture was stirred at 25 °C under N₂ for a further 12 h. When 11 was completely consumed (TLC), the reaction was quenched with sat. aq NH₄Cl (10 mL). The aqueous layer was extracted with EtOAc (3 × 25 mL), and the combined organic extracts were washed with brine (3 × 10 mL), dried (Na₂SO₄), filtered, and concentrated under reduced pressure. The resulting crude residue was purified by column chromatography [silica gel, hexane–EtOAc (80:20)] to give a colorless liquid; yield: 70.0 mg (87%); TLC: R_f = 0.25 (hexane–EtOAc, 70:30). [α]_D ²⁰ –20.4 (c 0.1, CH₂Cl₂). IR (CH₂Cl₂): 2963, 2920 (C–H), 1722, 1694 (C=O), 1685 (C=N), 1484, 1392 (C–H), 1170 (C–O), 1155 (S–O), 867 (=C–H), 775, 720 (C–H) cm^–1. ¹H NMR (400 MHz, CDCl₃, 25 °C): δ = 8.08 (s, 1 H, rotamer 1), 8.06 (s, 1 H, rotamer 2), 3.95 (s, 3 H, rotamer 1), 3.94 (s, 3 H, rotamer 2), 2.99–2.95 (m, 4 H, rotamers 1 + 2), 2.70 (s, 3 H, rotamer 1), 2.65 (s, 3 H, rotamer 2), 2.18–2.11 (m, 2 H, rotamers 1 + 2), 1.89–1.81 (m, 2 H, rotamers 1 + 2), 1.70–1.67 (m, 4 H, rotamers 1 + 2), 1.46 (s, 9 H, rotamer 1), 1.43 (s, 9 H, rotamer 2), 0.96 (t, J = 6.0 Hz, 6 H, rotamer 1), 0.85 (d, J = 6.5 Hz, 6 H, rotamer 2). ¹³C NMR (100 MHz, CDCl₃, 25 °C): δ = 171.9, 162.0, 156.6, 146.5, 127.2, 79.6, 60.3, 52.5, 30.73, 30.5, 30.0, 29.7, 28.4, 20.2, 19.9. Diagnostic signals of minor rotamer ¹³C NMR (100 MHz, CDCl₃, 25 °C): δ = 171.5, 161.9, 146.4, 79.2, 52.4, 20.1, 19.6. HRMS (ESI): m/z [M + H]⁺ calcd for C₁₇H₂₉N₂O₄S: 379.1662; found: 379.1675.

Zusatzmaterial

Supporting Information